Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226606 | 1.00 | GPR119 (0.47) | GPR119PDE4BUSP30TP53P2RX7 | |
| SCHEMBL5227765 | 1.00 | GPR119 (0.47) | GPR119PDE4BUSP30TP53P2RX7 | |
| SCHEMBL12435287 | 0.89 | OPRL1 (0.43) | HSD11B1TACR1CTSK | |
| SCHEMBL26399605 | 0.89 | OPRL1 (0.43) | HSD11B1TACR1CTSK | |
| SCHEMBL5444435 | 0.87 | PDE4B (0.51) | GPR119PDE4BTP53P2RX7HSD11B1 | |
| SCHEMBL5225674 | 0.87 | PDE4B (0.51) | GPR119PDE4BTP53P2RX7HSD11B1 | |
| SCHEMBL5444431 | 0.87 | PDE4B (0.51) | GPR119PDE4BTP53P2RX7HSD11B1 | |
| SCHEMBL19893581 | 0.84 | PDE4B (0.52) | GPR119PDE4BUSP30HSD11B1TACR1 | |
| SCHEMBL19893582 | 0.84 | PDE4B (0.52) | GPR119PDE4BUSP30HSD11B1TACR1 | |
| SCHEMBL19893583 | 0.84 | PDE4B (0.52) | GPR119PDE4BUSP30HSD11B1TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1789389-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006030984-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | AVPR1B, PRLHR, HRH4 | GPR119 155/4885PDE4B 1273/4885USP30 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.